Seno Medical Instruments, Inc.
3838 Medical Drive
47 articles about Seno Medical Instruments, Inc.
Alex Hamlow has joined Seno Medical Instruments, Inc. as Chief Revenue Officer. Seno Medical is the leader in improving the process of diagnosing breast cancer and the pioneer of the Imagio® Breast Imaging System with opto-acoustic/ultrasound (OA/US) imaging technology.
Carolina Breast Imaging Specialists, PLLC Is First in Nation to Adopt Groundbreaking Imagio® Breast Imaging System for Breast Cancer Diagnosis
Mammograms are an essential part of preventive healthcare, and when an initial review reveals a suspicious lesion, additional imaging and/or invasive breast biopsies could be the next step in diagnosis.
Seno Medical Inks Exclusive Agreement with Genetik, Inc. as Distributor for Imagio® Breast Imaging System in Southeast Asia
Seno Medical has entered into an exclusive distributor agreement with Genetik, Inc., to market, sell and service the company’s groundbreaking Imagio® Opto-Acoustic/Ultrasound Breast Imaging System.
Retrospective Study of Seno Medical’s Imagio® Breast Imaging System Published in American Journal of Roentgenology Shows System May Help Reduce Biopsies of Benign Breast Masses Compared to Ultrasound Alone
A retrospective study of Seno Medical‘s Imagio® Breast Imaging System published in the American Journal of Roentgenology found that the company’s opto-acoustic/ultrasound technology significantly improves specificity at fixed sensitivity compared to conventional ultrasound.
Seno Medical, makers of the Imagio® Breast Imaging System - a revolutionary new modality in breast imaging - will officially launch the commercially available system at the annual RSNA Scientific Assembly and Annual Meeting starting November 27 through December 1 in Chicago.
Seno Medical’s Imagio® Breast Imaging System has been named a finalist in the 2022 Medical Device Excellence Awards, in the Radiological, Imaging, and Electromechanical Devices category.
Seno Medical’s Imagio® Breast Imaging System Named Science and Medical Category Finalist in 2022 Edison Awards Program
Seno Medical’s Imagio® Breast Imaging System has been named a finalist in the 2022 Edison Awards competition in the Science and Medical category and Diagnostics sub-category.
Additional Research Published In Radiology Demonstrates Application Of Ground-Breaking Breast Cancer Diagnostic Technology
Seno Medical's opto-acoustic technology could differentiate between breast cancer types
Seno Medical's opto-acoustic technology could reduce false positives and identify cancer sub-types
Partnership emphasizes breast health education and empowers women
New Data Demonstrate That Seno Medical's Opto-Acoustic Imaging Technology Offers A Non-Invasive Approach to Differentiating Breast Cancer Molecular Subtypes
Company's technology, which shows promise as a clinical prognostic tool that may facilitate treatment decisions, featured as a High Impact Clinical Trial at the Radiological Society of North America Annual Meeting for second year in a row [11-December-2018] SAN ANTONIO , Dec. 11, 2018 /PRNewswire/ -- Seno Medical Instruments, Inc. (Seno Medical), the leader in new
San Antonio-based technology company focuses on improving breast cancer diagnostic accuracy and 'walking the talk' inside the company
The American Journal of Roentgenology recently published findings on statistical methods for downgrading the risk classification of breast masses to reduce the need for unnecessary breast biopsies.
Seno Medical Instruments Announces Recipient of its 8th Annual Best Paper Award During the SPIE Annual Conference
This year's award was given to a team of researchers from California Institute of Technology, Washington University in St. Louis, Duke University and Tsinghua University, Beijing who have developed a novel photo-acoustic technology.
Seno Medical Instruments Announces New Data Demonstrating That Imagio Opto-Acoustic Breast Imaging System Delivers Critical Diagnostic and Prognostic Information About Tumor Subtypes
The prospective, multi-center study was conducted at 16 centers in the United States.
Seno Medical Instruments' Imagio Opto-Acoustic Breast Imaging System Demonstrates Ability to Downgrade Risk Classification of Benign Breast Masses in a Prospective European Clinical Trial
The prospective, controlled, multi-center study was conducted at five centers in the Netherlands between March 2015 and February 2016.
Pivotal Trial Data Support Potential of Seno Medical Instruments' Imagio Opto-Acoustic Breast Imaging System in Reducing False Positive Breast Examinations and Benign Biopsies
The study found that OA/US was more specific than device gray-scale ultrasound alone in differentiating malignant from benign breast lesions and was non-inferior to US with respect to sensitivity.
Seno Medical Investigator Speaking To Opto-Acoustic Breast Imaging As A Strong Predictor Of Malignancy